Skip to main content
. 2013 Jun 20;8(6):e65487. doi: 10.1371/journal.pone.0065487

Table 7. Case-control studies on VDR rs731236 (Taq1) and risk for MS (NA =  data not available).

AUTHORS [REF] GROUP (N) GENOTYPE TT GENOTYPE Tt GENOTYPE tt ALLELE T ALLELE t
Partridge et al. [14] MS(402) 140(0.348) 203(0.505) 59(0.147) 483(0.601) 321(0.399)
Controls(231) 86(0.372) 106(0.459) 39(0.169) 278(0.602) 184(0.398)
OR(95% CI), p 0.90(0.63–1.28), 0.544 1.20(0.86–1.69), 0.264 0.85(0.53–1.35), 0.460 1.00(0.78–1.27), 0.973 1.00(0.79–1.28), 0.973
Tajouri et al. [16] MS(104) 27(0.260) 57(0.548) 20(0.192) 111(0.534) 97(0.466)
Controls(93) 42(0.452) 40(0.430) 11(0.118) 124(0.667) 62(0.333)
OR(95% CI), p 0.43(0.22–0.81), 0.005 1.61(0.88–2.94), 0.099 1.78(0.75–4.25), 0.155 0.58(0.37–0.88), 0.007 1.75(1.14–2.69), 0.007
Dickinson et al. [18] MS(136) 52(0.382) 68(0.500) 16(0.118) 172(0.632) 100(0.368)
Controls(235) 86(0.366) 108(0.459) 41(0.175) 280(0.596) 190(0.404)
OR(95% CI), p 1.07(0.68–1.70), 0.753 1.18(0.75–1.84), 0.453 0.63(0.32–1.22). 0.144 1.17(0.85–1.61), 0.325 0.86(0.62–1.18), 0.325
Smolders et al. [20] MS(212) 83(0.391) 96(0.453) 33(0.156) 262(0.618) 162(0.382)
Controls(289) 112(0.388) 138(0.477) 39(0.135) 362(0.626) 216(0.374)
OR(95% CI), p 1.02(0.70–1.49), 0.928 0.91(0.63–1.31), 0.585 1.18(0.70–2.01), 0.514 0.97(0.74–1.26), 0.787 1.04(0.79–1.35), 0.787
Simon et al. [15] MS(214) 86(0.402) 107(0.500) 21(0.098) 279(0.652) 149(0.348)
Controls(428) 154(0.360) 205(0.479) 69(0.161) 513(0.599) 343(0.401)
OR(95% CI), p 1.20(0.84–1.70), 0.300 1.09(0.77–1.53), 0.616 0.57(0.33–0.98), 0.030 1.25(0.98–1.61), 0.068 0.80(0.62–1.02), 0.068
Sioka et al. [21] MS(69) 30(0.435) 30(0.435) 9(0.130) 90(0.652) 48(0.348)
Controls(81) 33(0.408) 36(0.444) 12(0.148) 102(0.630) 60(0.370)
OR(95% CI), p 1.12(0.55–2.26), 0.736 0.96(0.48–1.93), 0.906 0.86(0.31–2.39), 0.756 1.10(0.67–1.82), 0.686 0.91(0.55–1.50), 0.686
Agliardi et al. [22] MS(641) 219(0.342) 308(0.480) 114(0.178) 746(0.582) 536(0.418)
Controls(558) 220(0.394) 249(0.446) 89(0.160) 689(0.617) 427(0.383)
OR(95% CI), p 0.80(0.63–1.02), 0.059 1.15(0.91–1.45), 0.236 1.14(0.83–1.56), 0.398 0.86(0.73–1.02), 0.077 1.16(0.98–1.37), 0.077
Cox et al. [19] MS(727) NA NA NA 843(0.580) 611(0.420)
Controls(604) NA NA NA 749(0.620) 459(0.380)
OR(95% CI), p 0.85(0.72–0.99), 0.035 1.18(1.01–1.39), 0.035
Irízar et al. [23] MS(136) 55(0.404) 70(0.515) 11(0.081) 180(0.662) 92(0.338)
Controls(337) 145(0.430) 157(0.466) 35(0.140) 447(0.663) 227(0.337)
OR(95% CI), p 0.90(0.59–1.38), 0.607 1.22(0.80–1.85), 0.337 0.76(0.35–1.61), 0.446 0.99(0.73–1.35), 0.966 1.01(0.74–1.37), 0.966
García-Martín et al.(Current study) MS(303) 129(0.426) 129(0.426) 45(0.148) 387(0.639) 219(0.361)
Controls(310) 131(0.423) 144(0.464) 35(0.113) 406(0.655) 214(0.345)
OR(95% CI), p 1.01(0.73–1.41), 0.937 0.86(0.61–1.19), 0.335 1.37(0.83–2.26), 0.191 0.93(0.73–1.19), 0.552 1.07(0.84–1.37), 0.552
TOTAL SERIES MS(2944) 821/1396(0.370) 1068/1149(0.482) 328/1889(0.148) 3553(0.603) 2335(0.397)
Controls(3166) 1009/1553(0.394) 1183/1379(0.462) 370/2192(0.144) 3950(0.624) 2382(0.376)
OR(95% CI), p 0.91(0.80–1.02), 0.095 1.08(0.97–1.22), 0.168 1.03(0.87–1.21), 0.730 0.92(0.85–0.99), 0.021 1.09(1.01–1.17), 0.021